Physicians, patients and experts from all over the world will gather in Las Vegas in November to discuss and raise awareness about LDN for therapies related to chronic pain, autoimmune diseases and other conditions. The LDN 2014 AIIC Conference 2014 will take place on the 7th and 8th November at the MEET in Las Vegas with a number of high profile medical experts confirmed to speak. The conference also coincides with LDN Awareness Week 2014 which runs from 2nd-8th November 2014. This interview is with Bernard Bihari, MD, (1931-2010), the discoverer of the clinical effects of low-dose naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr Bihari discovered the significant effectiveness of low-dose naltrexone in protecting the battered immune systems of those who were infected. As Dr Bihari explains, the immune system normalizing effect of the drug application he discovered applies to a wide range of autoimmune disorders. Link here for more on the conference.
Researchers at the University of Chicago found that after a long stay in the Intensive Care Unit (ICU) only a handful of pathogenic microbe species remain behind in patients’ intestines. The team tested these remaining pathogens and discovered that some can become deadly when provoked by conditions that mimic the body’s stress response to illness. “They’ve got a lot of bad guys in there, but the presence of bad guys alone doesn’t tell you who’s going to live or die,” says John Alverdy, a gastrointestinal surgeon and one of two senior authors on the study. “It’s not only which microbes are there, but how they behave when provoked by the harsh and hostile conditions of critical illness.” By John Alverdy et al, published in mBio®, journal of the American Society for Microbiology.